1LNTH Stock Overview

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. More details

1LNTH fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 56.1% below our estimate of its fair value

Earnings are forecast to grow 20.46% per year

Analysts in good agreement that stock price will rise by 59.2%

Risk Analysis

Shares are highly illiquid

Large one-off items impacting financial results

Profit margins (16.5%) are lower than last year (33.7%)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Lantheus Holdings, Inc. Competitors

DiaSorin

BIT:DIA

€5.1b

Svas Biosana

BIT:SVS

€40.9m

Amplifon

BIT:AMP

€4.4b

EL.En

BIT:ELN

€818.1m

Price History & Performance

Summary of share price highs, lows and changes for Lantheus Holdings
Historical stock prices
Current Share Price	US$72.12
52 Week High	US$0
52 Week Low	US$0
Beta	0.23
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-19.18%

Recent updates

Shareholder Returns

	1LNTH	IT Medical Equipment	IT Market
7D	1.2%	1.0%	2.9%
1Y	n/a	-5.6%	14.1%

Return vs Industry: Insufficient data to determine how 1LNTH performed against the Italian Medical Equipment industry.

Return vs Market: Insufficient data to determine how 1LNTH performed against the Italian Market.

Price Volatility

Is 1LNTH's price volatile compared to industry and market?
1LNTH volatility
1LNTH Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.9%
Market Average Movement	5.4%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1LNTH's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1LNTH's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1956	808	Brian Markison	www.lantheus.com

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart.

Lantheus Holdings, Inc. Fundamentals Summary

How do Lantheus Holdings's earnings and revenue compare to its market cap?
1LNTH fundamental statistics
Market cap	€4.95b
Earnings (TTM)	€228.10m
Revenue (TTM)	€1.38b

22.1x

P/E Ratio

3.7x

P/S Ratio

Is 1LNTH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1LNTH income statement (TTM)
Revenue	US$1.54b
Cost of Revenue	US$552.55m
Gross Profit	US$984.15m
Other Expenses	US$729.82m
Earnings	US$254.32m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	3.68
Gross Margin	64.04%
Net Profit Margin	16.55%
Debt/Equity Ratio	48.6%

How did 1LNTH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/16 10:19
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lantheus Holdings, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jeffrey Johnson	Baird
Yuan Zhi	B. Riley Securities, Inc.
Brian Kemp Dolliver	Brookline Capital Markets

Lantheus Holdings BIT:1LNTH Stock Report